The Metastatic Prostate Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Metastatic Prostate Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate Cancer Market.
Some of the key takeaways from the Metastatic Prostate Cancer Pipeline Report:
- Companies across the globe are diligently working toward developing novel Metastatic Prostate Cancer treatment therapies with a considerable amount of success over the years.
- Metastatic Prostate Cancer companies working in the treatment market are ORIC Pharmaceuticals, AstraZeneca plc, Orion Corporation, Regeneron Pharmaceuticals, Genentech, and others, are developing therapies for the Metastatic Prostate Cancer treatment
- Emerging Metastatic Prostate Cancer therapies in the different phases of clinical trials are- ORIC-944, AZD-5305, ODM 209, REGN2810, Atezolizumab, and others are expected to have a significant impact on the Metastatic Prostate Cancer market in the coming years.
- In February 2023, An ongoing Phase II clinical trial (the “TATCIST” trial) evaluating 225Ac-PSMA I&T, a small molecule targeting prostate-specific membrane antigen (“PSMA”) expressed on prostate cancers, was acquired by Fusion Pharmaceuticals from RadioMedix, Inc. The alpha-emitting radiopharmaceutical under evaluation in the TATCIST study will be referred to as FPI-2265 after the close.
- In February 2023, For the development and marketing of CRB-701 (SYS6002), a novel clinical-stage antibody drug conjugate (ADC) targeting Nectin-4, Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited, have entered into an exclusive licensing agreement. Exclusive commercialization rights for CRB-701 in the US, Canada, UK, Australia, EU (including the EU Free Trade Area), and EU are covered by the agreement. For SYS6002, all rights will stay with CSPC in the remaining international markets. The goal of the ongoing clinical development is to treat urothelial cancer as well as other solid tumors that are Nectin-4 positive, which may include prostate, lung, and breast cancer.
- In February 2023, After at least one previous line of chemotherapy for locally advanced or metastatic prostate cancer, patients with small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) received full data from BioXcel Therapeutics, Inc.’s Phase IIa trial of BXCL701, the company’s investigational oral innate immune activator, in combination with KEYTRUDA (pembrolizumab). The findings will be presented on February 16, 2023, at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, both as a poster and a quick abstract presentation.
- In January 2023, An update on the clinical development program for its first-in-class therapeutic candidate, AsiDNA, was provided by Onxeo S.A. Next Oncology San Antonio, Onxeo’s first clinical research location in the US, has been activated. This multicenter, phase I/II basket trial aims to evaluate the safety and initial efficacy of AsiDNA in combination with olaparib in patients who have advanced from prior PARP inhibitor therapy and have recurrent ovarian, breast, or metastatic castration-resistant prostate cancer (mCRPC).
Metastatic Prostate Cancer Overview
Prostate cancer that has “metastasized,” or spread to other parts of the body, is known as metastatic prostate cancer (MPC). Prostate cancer typically metastasizes to lymph nodes or bones. Additionally, it frequently spreads to the lungs or liver.
Get a Free Sample PDF Report to know more about Metastatic Prostate Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight
Emerging Metastatic Prostate Cancer Drugs Under Different Phases of Clinical Development Include:
- ORIC-944: ORIC Pharmaceuticals
- AZD-5305: AstraZeneca plc
- ODM 209: Orion Corporation
- REGN2810: Regeneron Pharmaceuticals
- Atezolizumab: Genentech
Metastatic Prostate Cancer Route of Administration
Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intravenous
- Intradermal
- Intra-tumoral
- Oral
- Parenteral
- Subcutaneous etc.
- Mechanism of Action
Metastatic Prostate Cancer Molecule Type
Metastatic Prostate Cancer Products have been categorized under various Molecule types, such as
- Luteinizing hormone-releasing hormone (LHRH) (GnRH) Agonists
- Luteinizing hormone-releasing hormone (LHRH) (GnRH) Agonists
- Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
- Vascular endothelial growth factor inhibitors
- Androgen receptor antagonists
- Cytotoxic T-lymphocyte antigen 4 inhibitors
- Programmed cell ligand 1 (PD-L1) Inhibitors
- Programmed cell ligand 1 (PD-L1) Inhibitors
- AKT inhibitors
- Polo like Kinase 1 (PLK1) inhibitor
- Adenosine A2A receptor antagonists
- SSRP1 protein inhibitors
- Cyclin-dependent kinase 4 inhibitors
- Indoleamine-pyrrole 2,3-dioxygenase inhibitors
- Cytochrome P 450 enzyme system inhibitors
- Glutamate carboxypeptidase II inhibitors
- Fibroblast growth factor receptor antagonists
- Transforming growth factor beta type I receptor antagonists
- HSP70 heat shock protein inhibitors
- Wnt signalling pathway modulators
- Stem cell markers suppression
- CD46 protein Inhibitors
- CD3 antigen inhibitors
- Tubulin inhibitors
- Calcitriol receptor agonists
- ROS1 protein inhibitors
- Insulin-like growth factor I inhibitors
- Insulin-like growth factor II inhibitors etc.
- Molecule Type
- Antibodies
- Cell Therapies Immunotherapies
- Liposome
- Microbiome
- Peptides
- Recombinant fusion proteins
- Small molecules
- Small interfering RNAs
- Vaccines
- Vitamin D analogues and others
Metastatic Prostate Cancer Pipeline Therapeutics Assessment
- Metastatic Prostate Cancer Assessment by Product Type
- Metastatic Prostate Cancer By Stage and Product Type
- Metastatic Prostate Cancer Assessment by Route of Administration
- Metastatic Prostate Cancer By Stage and Route of Administration
- Metastatic Prostate Cancer Assessment by Molecule Type
- Metastatic Prostate Cancer by Stage and Molecule Type
DelveInsight’s Metastatic Prostate Cancer Report covers around 110+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Metastatic Prostate Cancer product details are provided in the report. Download the Metastatic Prostate Cancer pipeline report to learn more about the emerging Metastatic Prostate Cancer therapies
Some of the key companies in the Metastatic Prostate Cancer Therapeutics Market include:
Key companies developing therapies for Metastatic Prostate Cancer are – Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research, and others.
Metastatic Prostate Cancer Pipeline Analysis:
The Metastatic Prostate Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Prostate Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer Treatment.
- Metastatic Prostate Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Prostate Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Metastatic Prostate Cancer drugs and therapies
Metastatic Prostate Cancer Pipeline Market Drivers
- Increasing Prevalence of Prostate Cancer, increase in research and development activities for metastatic prostate cancer are some of the important factors that are fueling the Metastatic Prostate Cancer Market.
Metastatic Prostate Cancer Pipeline Market Barriers
- However, high cost associated with the treatment, side-effects associated with the treatment of Prostate Cancer and other factors are creating obstacles in the Metastatic Prostate Cancer Market growth.
Scope of Metastatic Prostate Cancer Pipeline Drug Insight
- Coverage: Global
- Key Metastatic Prostate Cancer Companies: ORIC Pharmaceuticals, AstraZeneca plc, Orion Corporation, Regeneron Pharmaceuticals, Genentech, and others
- Key Metastatic Prostate Cancer Therapies: ORIC-944, AZD-5305, ODM 209, REGN2810, Atezolizumab, and others
- Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies
- Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers
Request for Sample PDF Report for Metastatic Prostate Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Metastatic Prostate Cancer Report Introduction
2. Metastatic Prostate Cancer Executive Summary
3. Metastatic Prostate Cancer Overview
4. Metastatic Prostate Cancer- Analytical Perspective In-depth Commercial Assessment
5. Metastatic Prostate Cancer Pipeline Therapeutics
6. Metastatic Prostate Cancer Late Stage Products (Phase II/III)
7. Metastatic Prostate Cancer Mid Stage Products (Phase II)
8. Metastatic Prostate Cancer Early Stage Products (Phase I)
9. Metastatic Prostate Cancer Preclinical Stage Products
10. Metastatic Prostate Cancer Therapeutics Assessment
11. Metastatic Prostate Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Metastatic Prostate Cancer Key Companies
14. Metastatic Prostate Cancer Key Products
15. Metastatic Prostate Cancer Unmet Needs
16 . Metastatic Prostate Cancer Market Drivers and Barriers
17. Metastatic Prostate Cancer Future Perspectives and Conclusion
18. Metastatic Prostate Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services